In Debate Over Antidepressants,
FDA Weighed Risk of False Alarm

WASHINGTON -- Last December, drug-safety analyst Andrew Mosholder delivered a blunt message to his colleagues at the Food and Drug Administration: Young people taking antidepressants were more likely to become suicidal.

That conclusion, based on Dr. Mosholder's analysis of clinical trials comparing youths who took the drugs with those who took a placebo, set off a still-raging debate over whether the benefits of antidepressants outweigh the risks for children and teens. It's a question of keen interest for the...